Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare. The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry. Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.

Share:
More In Science
RoadRunner Raises $70 Million Series D to Fund National Expansion and Accelerate Sustainability Solutions
Technology-driven sustainable waste management platform, RoadRunner Recycling, recently raised a $70 million Series D round from BeyondNetZero, the climate investing venture of General Atlantic. RoadRunner says it creates and manages end-to-end waste and recycling solutions for businesses of all sizes and that its proprietary technology can boost cost savings and improve recycling rates for companies, which in turn drives sustainability for the waste industry and our world. RoadRunner Recycling founder and CEO Graham Rihn joined Cheddar News' Closing Bell to discuss.
Load More